Dear All, I wrote previously (23 Sep 2025 newsletter, “EU’s €253 million, 10-year One Health AMR (OHAMR) Initiative”) about OHAMR (European Partnership on One Health AMR ), the 10-year AMR funding initiative that is the successor to the JPIAMR program. OHAMR have now announced that they will be opening a call on 18 Nov 2025 with

Note: World Antibiotic Awareness Week begins tomorrow and there are multiple updates to the meeting calendar … please look for the red text in the meeting calendar! Dear All, For those of you in the UK, particularly if you are based in the London area, there’s a chance for you to be part of the upcoming

Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its fire extinguisher-like values) comes up often. As a reminder, the STEDI values are Spectrum, Transmission, Enablement, Diversity, and Insurance. As a good example, consider Enablement: knowing that an antibiotic exists as a backup makes safe

Dear All, I’ve written in the past about the creative work done by the Milken Institute on health care financing (26 Mar 2022 newsletter, “Pull mechanisms: Private capital can multiply Subscription (Netflix) and TEV models!”). Milken recently held a 3-day symposium entitled “The Future of Health Summit” (4-6 Nov 2025) during which there was an

Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of the reports: Preclinical pipeline dashboard Clinical pipeline dashboard Underlying .xlsx dataset And for reference, don’t forget that you can find a comparative summary of the priority pathogen lists on this

Dear All, WHO have just (2 Oct 2025) released a pair of reports on therapeutics and diagnostics for bacterial pathogens, with a focus on how these advance our tools for priority bacterial pathogens. Here are the links you need: WHO 2025 update on the preclinical and clinical antibacterial pipeline Title: “Analysis of antibacterial agents in

Dear All, When I wrote earlier this year (23 Jan 2025 newsletter) that the January 2025 PACCARB meeting (Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria) had been cancelled, we had all hoped this would be a transient adjustment and that the very important work of PACCARB would resume in due course.  Unfortunately, this has

Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of  ‘transferable data exclusivity voucher’ (TEV), also referred to as a  ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV